Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Moolec Science ( (MLEC) ) has provided an announcement.
On October 2, 2025, Moolec Science received a notice from INVIM Corporativo S.L. alleging a breach of an Assignment and Assumption Agreement related to a $13 million payment. Moolec disputes the claim, arguing that INVIM did not fulfill certain conditions precedent, and has formally rejected the allegations. The company plans to defend its position, but acknowledges that an adverse ruling could significantly impact its financial condition.
The most recent analyst rating on (MLEC) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Moolec Science stock, see the MLEC Stock Forecast page.
Spark’s Take on MLEC Stock
According to Spark, TipRanks’ AI Analyst, MLEC is a Underperform.
Moolec Science faces significant financial challenges with negative profitability and cash flow issues despite revenue growth. The technical analysis is bearish, and the valuation appears unfavorable with a negative P/E ratio. These factors contribute to a low overall stock score, highlighting the need for improved financial performance and market sentiment.
To see Spark’s full report on MLEC stock, click here.
More about Moolec Science
Moolec Science operates in the biotechnology industry, focusing on developing innovative solutions for the agricultural sector. The company specializes in molecular farming, producing animal proteins in plants, and aims to enhance food security and sustainability.
Average Trading Volume: 186,234
Technical Sentiment Signal: Sell
Current Market Cap: $7.2M
See more insights into MLEC stock on TipRanks’ Stock Analysis page.